Correlation between human equilibrative nucleoside transporter 1 expression and chemotherapy sensitivity of gemcitabine and vinorelbine in patients with advanced non-small-cell carcinoma
Lou Jun
Sheng Yu
Wu Minli
Tang Wanfen
Abstract：Objective To evaluate the relevance between the gemcitabine chemotherapy sensitivity and the expression level of human equilibrative nucleoside transporter 1 (hENT1) after non-small-cell carcinoma (NSCLC) operation.Methods A total of 47 NSCLC patients were divided into GP group (23 patients) and NP group (24 patients) by random digit grouping method.GP group received gemcitabine and cisplatin chemotherapy.Cisplatin was used intravenously at the dose of 80 mg/m2 from the 1st to 3rd days and gemcitabine was used intravenously at the dose of 800 to 1 250 mg/m2 on the 1st and 8th day.NP group received gemcitabine and cisplatin chemotherapy.Cisplatin was used intravenously as above and vinorelbine was used intravenously at the dose of 25 mg/m2 on the 1st and 8th day.The expression level of hENT1 in lung cancer paraffin block specimens of the 47 NSCLC patients after operation was tested by immunohistochemical SP method; more than 2 cycles' chemotherapy were implemented by Gemcitabine and vinorelbine.The patients' life cycles were followed up and the relevance among gemcitabine chemotherapy sensitivity and the hENT1 expression level were evaluated.Results progressionfree survival of hENT1 high expression was (28 ± 18) months in GP group,(24 ± 16) months in the NP group,the differences between the two groups was significant (P =0.042),high expression median progression-free survival was 32 months in the GP group,and 22 months in the NP group,the difference between both groups was significant (P =0.037).GP group had a median survival of 35 months after chemotherapy in the low expression of hENT1,while NP group had a median survival of 34 months after chemotherapy in the low expression of hENT1 ; the two groups had no significant difference (P ＞ 0.05).Conclusions Degree of hENT1 expression associated with the chemosensitivity of gemcitabine.It may become a new target of gemcitabine chemotherapy for NSCLC.
Keywords：Human equilibrative nucleoside transporter 1Non-small-cell carcinoma,advancedGemcitabineVinorelbine
Publication Date：2015-02-28
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 165-169 )